Paul-Ehrlich-Institut

COVID-19 Vac­cines

Proof of complete immunisation

Primary immunisation must be completed with one or more vaccines in order to be considered as proof of complete immunisation against the coronavirus SARS-CoV-2. The applicable requirements are detailed in section 22a of the Infection Protection Act.

Section 22a of the Infection Protection Act (IfSG) (German only)

List of COVID-19 Vaccines with a marketing authorisation

COVID-19 vaccines are indicated for active immunisation to prevent COVID-19 disease caused by the SARS-CoV-2 virus.

Name De­scrip­tion Mar­ket­ing Au­tho­ri­sa­tion Hold­er Kind of Vac­cine Li­cense Num­ber Li­cense Date Further Information

Vaxzevria (COVID-19 Vac­cine As­traZeneca)

COVID-19-Impf­stoff (Vek­tor-Impf­stoff)

Ver­wen­dung ab einem Leben­salter von 18 Jahren / Use from 18 years of age on­wards

As­traZeneca AB, Schwe­den

Mono EU/1/21/1529 29.01.2021

EPAR: Vaxzevria (COVID-19 Vac­cine As­traZeneca)

Pro­duk­t­in­for­ma­tion: Vaxzevria (COVID-19 Vac­cine As­traZeneca)

Prod­uct In­for­ma­tion: Vaxzevria (COVID-19 Vac­cine As­traZeneca)

Rote-Hand-Brief: Vaxzevria / COVID-19 Vac­cine As­traZeneca (13.10.2021)

Rote-Hand-Brief: Vaxzevria / COVID-19 Vac­cine As­traZeneca (23.06.2021)

Rote-Hand-Brief: Vaxzevria / COVID-19 Vac­cine As­traZeneca (02.06.2021)

Rote-Hand-Brief: Vaxzevria / COVID-19 Vac­cine As­traZeneca (13.04.2021)

Rote-Hand-Brief: COVID-19 Vac­cine As­traZeneca (24.03.2021)

19.03.2021: In­for­ma­tion für Ärztin­nen und Ärzte - COVID-19-Impf­stoff As­traZeneca

19.03.2021: In­for­ma­tion for Physi­cians - COVID-19 Vac­cine As­traZeneca

Spike­vax (COVID-19 Vac­cine Mod­er­na)

COVID-19-Impf­stoff (mR­NA)

Ver­wen­dung ab einem Leben­salter von 6 Jahren / Use from 6 years of age on­wards

Mod­er­na Biotech Spain, S.L.

Mono EU/1/20/1507 06.01.2021

EPAR: Spike­vax (COVID-19 Vac­cine Mod­er­na)

Pro­duk­t­in­for­ma­tion: Spike­vax (COVID-19 Vac­cine Mod­er­na)

Prod­uct In­for­ma­tion: Spike­vax (COVID-19 Vac­cine Mod­er­na)

Rote-Hand-Brief: BioN­Tech und Mod­er­na zu den Impf­stof­fen Comir­naty und Spike­vax (19.07.2021)

Nu­vax­ovid (NVX-CoV2373)

COVID-19-Impf­stoff (Pro­tein­basiert­er Impf­stoff)

Ver­wen­dung ab einem Leben­salter von 18 Jahren / Use from 18 years of age on­wards

No­vavax CZ a.s.

Mono EU/1/21/1618 20.12.2021

EPAR: Nu­vax­ovid

Pro­duk­t­in­for­ma­tion: Nu­vax­ovid

Prod­uct In­for­ma­tion: Nu­vax­ovid

Jcov­den (COVID-19 Vac­cine Janssen)

COVID-19-Impf­stoff (Vek­tor-Impf­stoff)

Ver­wen­dung ab einem Leben­salter von 18 Jahren / Use from 18 years of age on­wards

Janssen-Cilag In­ter­na­tion­al NV

Mono EU/1/20/1525 11.03.2021

EPAR: Jcov­den (COVID-19 Vac­cine Janssen)

Pro­duk­t­in­for­ma­tion: Jcov­den (COVID-19 Vac­cine Janssen)

Prod­uct In­for­ma­tion: Jcov­den (COVID-19 Vac­cine Janssen)

Rote-Hand-Brief: COVID-19 Vac­cine Janssen (13.10.2021)

Rote-Hand-Brief: COVID-19 Vac­cine Janssen (19.07.2021)

Rote-Hand-Brief: COVID-19 Vac­cine Janssen (26.04.2021)

Comir­naty

COVID-19-Impf­stoff (mR­NA)

Ver­wen­dung ab einem Leben­salter von 5-11 Jahren (10 µg) / Use from 5-11 years of age on­wards (10 µg)

Ver­wen­dung ab einem Leben­salter von 12 Jahren (30 µg) / Use from 12 years of age on­wards (30 µg)

BioN­Tech Man­u­fac­tur­ing GmbH

Mono EU/1/20/1528 21.12.2020

EPAR: Comir­naty

Pro­duk­t­in­for­ma­tion: Comir­naty

Prod­uct In­for­ma­tion: Comir­naty

An­wen­dung von Comir­naty für 5- bis 11-jährige Kinder – wichtige Hin­weise für Ärztin­nen und Ärzte

Use of Comir­naty for 5- to 11-Year-Old Chil­dren - Im­por­tant In­for­ma­tion for Med­i­cal Doc­tors

Rote-Hand-Brief: BioN­Tech und Mod­er­na zu den Impf­stof­fen Comir­naty und Spike­vax (19.07.2021)

Disclaimer

The vaccine list contains the preparations that have a valid authorisation from the European Commission. It does not provide any information about whether the preparations are available on the market.

Updated: 29.04.2022